Unicycive Therapeutics IncNASDAQ:UNCY
- LAST PRICE1.0700
- TODAY'S CHANGE (%)-0.0800 (-6.9565%)
- Bid / Lots1.0500/ 16
- Ask / Lots1.1000/ 3
- Open / Previous Close1.1700 / 1.1500
- Day Range
- 52 Week Range
- Volume243,117
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | UNCY |
|---|---|---|
| 09:32 ET | 1948 | 1.17 |
| 09:34 ET | 3358 | 1.1601 |
| 09:36 ET | 2796 | 1.17 |
| 09:39 ET | 3900 | 1.1601 |
| 09:43 ET | 4900 | 1.1607 |
| 09:45 ET | 6840 | 1.1607 |
| 09:48 ET | 500 | 1.175 |
| 09:50 ET | 1000 | 1.1881 |
| 09:52 ET | 1400 | 1.1881 |
| 09:54 ET | 1000 | 1.1899 |
| 10:01 ET | 6100 | 1.1601 |
| 10:03 ET | 3296 | 1.17 |
| 10:10 ET | 3800 | 1.1601 |
| 10:12 ET | 2400 | 1.1607 |
| 10:15 ET | 1100 | 1.15 |
| 10:17 ET | 9935 | 1.16 |
| 10:21 ET | 5915 | 1.1601 |
| 10:24 ET | 2213 | 1.13 |
| 10:26 ET | 400 | 1.14 |
| 10:32 ET | 2115 | 1.14 |
| 10:39 ET | 1579 | 1.1499 |
| 10:42 ET | 1900 | 1.14 |
| 10:46 ET | 3899 | 1.1305 |
| 11:04 ET | 2500 | 1.135 |
| 11:22 ET | 300 | 1.1396 |
| 11:24 ET | 7416 | 1.1399 |
| 11:26 ET | 1000 | 1.14 |
| 11:27 ET | 254 | 1.1398 |
| 11:44 ET | 100 | 1.135 |
| 11:47 ET | 400 | 1.135 |
| 11:54 ET | 1000 | 1.1399 |
| 11:56 ET | 3000 | 1.1399 |
| 12:02 ET | 3579 | 1.125 |
| 12:03 ET | 3078 | 1.13 |
| 12:09 ET | 4400 | 1.12 |
| 12:14 ET | 600 | 1.11 |
| 12:16 ET | 11408 | 1.11 |
| 12:18 ET | 8200 | 1.1101 |
| 12:20 ET | 100 | 1.1197 |
| 12:30 ET | 5000 | 1.115 |
| 12:32 ET | 100 | 1.115 |
| 12:48 ET | 164 | 1.1199 |
| 12:52 ET | 700 | 1.115 |
| 01:06 ET | 300 | 1.1107 |
| 01:12 ET | 2850 | 1.1196 |
| 01:19 ET | 7264 | 1.1198 |
| 02:02 ET | 4100 | 1.11 |
| 02:06 ET | 800 | 1.11 |
| 02:09 ET | 800 | 1.11 |
| 02:20 ET | 111 | 1.11 |
| 02:24 ET | 5529 | 1.1 |
| 02:26 ET | 1000 | 1.1 |
| 02:27 ET | 11400 | 1.095 |
| 02:29 ET | 2000 | 1.1 |
| 02:36 ET | 100 | 1.09 |
| 02:38 ET | 1100 | 1.0901 |
| 02:40 ET | 500 | 1.0999 |
| 02:54 ET | 1000 | 1.0996 |
| 03:07 ET | 13373 | 1.09 |
| 03:09 ET | 14693 | 1.09 |
| 03:18 ET | 10263 | 1.0808 |
| 03:20 ET | 7197 | 1.09 |
| 03:30 ET | 2365 | 1.085 |
| 03:34 ET | 3903 | 1.08 |
| 03:36 ET | 100 | 1.07 |
| 03:38 ET | 1000 | 1.08 |
| 03:39 ET | 3200 | 1.0799 |
| 03:41 ET | 463 | 1.0799 |
| 03:43 ET | 100 | 1.0799 |
| 03:48 ET | 200 | 1.075 |
| 03:52 ET | 100 | 1.075 |
| 03:56 ET | 200 | 1.075 |
| 03:57 ET | 7693 | 1.07 |
| 03:59 ET | 1117 | 1.07 |
Apr 15, 2024
DJ Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark, from 11:10AM ET on Monday Apr 15, 2024 by Dow Jones
11:10AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 10, 2024
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, from 7:03AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:03AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 4, 2024
DJ Unicycive Therapeutics Initiated at Overweight by Piper Sandler, from 7:13AM ET on Thursday Apr 04, 2024 by Dow Jones
7:13AM ET on Thursday Apr 04, 2024 by Dow Jones
Apr 1, 2024
DJ Unicycive Therapeutics Price Target Maintained With a $4.50/Share by HC Wainwright & Co., from 6:26AM ET on Monday Apr 01, 2024 by Dow Jones
6:26AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 28, 2024
Press Release: Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update, from 4:15PM ET on Thursday Mar 28, 2024 by Dow Jones
4:15PM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Unicycive Therapeutics Inc | 40.0M | -0.7x | --- |
Clene Inc. | 42.8M | -0.6x | --- |
Carmell Corp | 39.8M | -1.4x | --- |
ProMIS Neurosciences Inc | 39.1M | -1.7x | --- |
Estrella Immunopharma Inc | 39.0M | -0.5x | --- |
Xilio Therapeutics Inc | 37.9M | -0.4x | --- |
Company Information
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Contact Information
- Headquarters
- 4300 El Camino Real, Suite 210LOS ALTOS, CA, United States 94022
- Phone
- 650-384-0642
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Shalabh Gupta
- Chief Financial Officer
- John Townsend
- Executive Vice President - Pharmaceutical and Business Operations
- Pramod Gupta
- Executive Vice President, Corporate Strategy
- Doug Jermasek
- Director
- Sara Kenkare-Mitra
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $40.0M |
|---|---|
Revenue (TTM) | $675.0K |
Shares Outstanding | 34.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.62 |
Book Value | $-0.11 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 59.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,077.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
